VERASTEM ONCOLOGY
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 500, Needham, Massac...Phone Number
(781) 292-4200Website
www.verastem.comRevenue
$49.6 MillionStock Symbol
VSTMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About VERASTEM ONCOLOGY
Verastem Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for patients with cancers driven by abnormalities in the RAS and MAPK signaling pathways. The company is dedicated to advancing targeted therapies that address significant unmet medical needs by focusing on the underlying biological mechanisms responsible for cancer development, progression, and resistance to treatment.Explore more
VERASTEM ONCOLOGY Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VERASTEM ONCOLOGY your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if VERASTEM ONCOLOGY has recently received funding, and reach out quickly before it becomes old news!
VERASTEM ONCOLOGY, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once VERASTEM ONCOLOGY has new funding data
Earning: See what the market has to say on VERASTEM ONCOLOGY recently announced quarterly report
Check out if VERASTEM ONCOLOGY is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when VERASTEM ONCOLOGY launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at VERASTEM ONCOLOGY
Click to see if VERASTEM ONCOLOGY had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at VERASTEM ONCOLOGY
Find more new buyers
Compare Similar Companies to VERASTEM ONCOLOGY
Compare insights from companies similar to VERASTEM ONCOLOGY, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
VERASTEM ONCOLOGY is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VERASTEM ONCOLOGY is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VERASTEM ONCOLOGY.
VERASTEM ONCOLOGY financials insights
Gather financial insights about VERASTEM ONCOLOGY, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Stock Offering
$63.3M
Unspecified
$2M
2014
Other Financing Round
$3.9M
2015
Stock Offering
$50.9M
2017
Stock Offering
$25M
2018
Multiple Rounds
$131.1M
2020
Debt
$4.8M
Share Placement
$100M
2022
Debt
$150M
VERASTEM ONCOLOGY Tech Stack
A closer look at the technologies used by VERASTEM ONCOLOGY
Most Recent Scoops
Open Position
Open Position
Hiring Plans
VERASTEM ONCOLOGY has more open roles in Engineering & Technical than it has had at any time in the past 12 months.
Hiring Plans
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
VERASTEM ONCOLOGY News & Media
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data.Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Yahoo Finance
BOSTON, May 26, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026.Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment
Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KRAS G12D (on/off) inhibitor, in patients with KRAS G12D-mutant solid tumors. The preliminary safety and tolerability data indicate that VS-7375 can […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VERASTEM ONCOLOGY
Sign Up For FreeTo access detailed company insights
Verastem Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for patients with cancers driven by abnormalities in the RAS and MAPK signaling pathways. The company is dedicated to advancing targeted therapies that address significant unmet medical needs by focusi... Read More
